Azome Therapeutics Inc
Tuesday, June 04, 2024
Inflammation
Company Presentation Theater 3
Azome Therapeutics was founded by University of Florida’s Chair of Pediatrics, Dr. Rashmin Savani and former Mallinckrodt Pharmaceuticals executives with a mission to revolutionize the treatment of inflammatory diseases. We are focused on severe acute inflammatory diseases and injuries that share a common biological mechanism: the NLRP3 Inflammasome. These inflammasome-mediated diseases include bronchopulmonary dysplasia (BPD), acute respiratory distress syndrome (ARDS), exacerbations in idiopathic lung fibrosis (ILF), acute lung injury, acute kidney injury, and sepsis. By specifically targeting the earliest activation signal for inflammasome activation, Azome’s technology represents a platform approach for addressing these severe unmet clinical needs.
Company Website:
http://www.azometherapeutics.com
Lead Product in Development:
Azome Therapeutics’ lead drug AZM-152 will be a first in class, highly effective treatment for a wide variety of inflammatory diseases and injuries including acute respiratory distress syndrome. By specifically targeting the earliest activation signal for inflammasome activation, Azome’s technology represents a platform approach for addressing these severe unmet clinical needs.
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Company HQ City
MALVERN
Company HQ State
PA
Company HQ Country
United States
CEO/Top Company Official
Elliott Gruskin
Development Phase of Primary Product
Pre-Clinical
Primary Speaker
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())